Food and Drug Administration
July 27, 2004
Slides
Alimta® (Pemetrexed) as a Second-Line Treatment for Patients With Non-Small Cell Lung Cancer, Dr. Paolo Paoletti, MD, Eli Lilly and Co. (HTM) (PPT)
Backup Slides, Eli Lilly and Co. (HTM) (PPT)
Presentation by Dr. Martin Cohen, MD, FDA (HTM) (PPT)
Efficacy Analyses - Alimta (NDA 21-677) Review, Yong-Cheng Wang, FDA (HTM) (PPT)
Open Public Hearing